Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial [Phase 2]

View source ↗

Summary

This release summarizes Phase 2 trial results evaluating the efficacy, safety, and pharmacokinetics of ulimorelin in patients with enteral feeding intolerance (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enteral Feeding Intolerance

Drugs mentioned

• Ulimorelin (ulimorelin)

Snippet

Sponsor: Lyric Pharmaceuticals | Conditions: Enteral Feeding Intolerance (EFI) | Phase 2 | Status: COMPLETED